Theralase bringing a Technology to Fight Bladder Cancer
Killing bladder cancer with new treatment
- Bladder removal
- Therefore, it is complex and costly procedure, with numerous quality of life impacts.
Thus, Theralase is developing an alternative treatment for BCG-Unresponsive patients. In which the bladder is filled with a light sensitive drug solution called TLD-1433. It is one which localizes specifically to the bladder cancer.
- Cancer cells, fibre optics are inserted into the bladder
- A laser is used to light activate the drug to destroy the bladder cancer cells from the inside out, leaving the bladder intact.
- The liquid in the bladder is then voided and the dead cancer cells excreted.
Theralase is working to bring this product to market in the next 3 years.
Theralase® Technologies Inc. is a biopharmaceutical company headquartered in Toronto, Canada focused on the design, development, manufacturing, and sale of patented laser technology platforms used in a wide range of bio-stimulative and bio-destructive clinical applications in patients.
Founded in 1994, Theralase’s operations are divided into two divisions: the production of therapeutic laser technology for commercial applications, and the research and development of laser-based technologies for the destruction of cancer cells and other disease states.
For more information on Theralase Technologies Inc. (TLT:TSX.V, TLTFF:OTCQB) please fill out the form below.